

ACTA MEDICINAE 6/2014 Pneumologie

Kompletní literatura

- 2 Možnosti biologické léčby u nemalobuněčného karcinomu plic v České republice**
prof. MUDr. Jana Skříčková, CSc. | MUDr. Bohdan Kadlec, Ph.D. | MUDr. Ondřej Venclíček | MUDr. Marcela Tomíšková
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
- 2 Crizotinib – další reálná možnost personalizované léčby nemocných s NSCLC v České republice**
prof. MUDr. Vítězslav Kolek, DrSc. Klinika plicních nemocí a TBC LF UP a FN Olomouc prof. MUDr. Miloš Pešek, CSc. Klinika plicních nemocí FN Plzeň prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC FN Brno MUDr. Ivona Grygárková Klinika plicních nemocí a TBC LF UP a FN Olomouc MUDr. Marcela Tomíšková Klinika nemocí plicních a TBC FN Brno MUDr. Jaromír Roubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN Ostrava MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN Praha MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha MUDr. Helerna Čoupková Klinika komplexní a onkologické péče MOÚ Brno
- 3 Gefitinib v první linii léčby nemalobuněčného karcinomu plic s prokázanou aktivační mutací genu EGFR u pacientů nad 80 let**
MUDr. Markéta Černovská Pneumologická klinika 1. LF UK Praha/Thomayerova nemocnice Praha
- 3 Ultibro® Breezhaler® – duální bronchodilatace fixní kombinací indakaterol/glykopyrronium v léčbě chronické obstrukční plicní nemoci**
prof. MUDr. Vítězslav Kolek, DrSc. Klinika plicních nemocí a tuberkulózy, FN Olomouc
- 3 Zánětlivé buňky u chronické obstrukční plicní nemoci**
MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a TBC, FN a LF UP Olomouc
- 3 Roflumilast ve světle nových doporučení pro léčbu chronické obstrukční plicní nemoci**
MUDr. Michal Švarc Plicní klinika FN a LF UK, Hradec Králové
- 4 Současná bronchologie**
MUDr. Jiří Votruba | MUDr. Hana Bartáková | MUDr. Juraj Šimovič 1. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha MUDr. Michal Šotola Centrum plicní endoskopie interního oddělení Nemocnice Na Homolce, Praha
- 4 Asthma bronchiale: farmakoterapie u dospělých prizmatem doporučení GINA 2014**
MUDr. Viktor Kašák LERYMED, s. r. o., Oddělení respiračních nemocí Praha
- 4 Problematické těžké asthma bronchiale**
MUDr. Vratislav Sedlák, Ph.D. | MUDr. Ondřej Kudela | MUDr. Vladimír Koblížek, Ph.D.
Plicní klinika LF a FN Hradec Králové, UK v Praze
- 5 Cystická fibróza dospělých**
MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN Motol
- 6 Léčba akutního srdečního selhání**
MUDr. Tomáš Janota, CSc. 3. interní klinika VFN a 1. LF UK, Praha
- 6 Léčba průjmových onemocnění**
MUDr. Helena Ambrožová, Ph.D. I. infekční klinika 2. LF UK a Nemocnice Na Bulovce
- 6 Narušení cirkadiánních rytmů a civilizační choroby**
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Možnosti biologické léčby u nemalobuněčného karcinomu plic v České republice

prof. MUDr. Jana Skříčková, CSc. | MUDr. Bohdan Kadlec, Ph.D. | MUDr. Ondřej Venclíček |
MUDr. Marcela Tomášková Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

- Dušek, I. – Májek, O. – Mužík, J. – Koptíková, J. – Pavlík, T. – Skříčková, J.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v ČR. In: Skříčková, J. – Koleček, V., et al.: *Základy moderní pneumologie*. Maxdorf, 2012, s. 490.
- Pešek, M.: Nemalobuněčný karcin plic. EUNI, <http://www.euni.cz/tema.php>.
- Skříčková, J. – Čoupek, P. – Babičková, L. – Tomášková, M. – Kaplanová, J. – Princ, D. – Kadlec, B. – Špelda, S.: Léčebné postupy u nemalobuněčného karcinomu plic. *Klin Onkol*, 2008, 21, s. 317–329.
- Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non-small cell lung cancer. *Eur Respir J*, 2009, 33, s. 915–930.
- Bonomi, P.: Clinical studies with non-irressa EGFR tyrosine kinase inhibitors. *Lung Cancer*, 2003, 41, s. S43–S48.
- Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the Epidermal Growth Factor Receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, 350, s. 2129–2139.
- Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, 2009, 361, s. 947–957.
- Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- Gridelli, C. – Rossi, A.: EORTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. *J Thorac Dis*, 2012, 4, s. 219–220, doi: 10.3978/j.issn.2072-1439.2012.03.03.
- Yang, J. C. H. – Schuler, M. – Yamamoto, N. – O'Byrne, K. – Hirsh, V. – Tony Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, abstrakt LBA7500.
- Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 2415.
- Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- Shaw, A. T. – Yeap, B. Y. – Solomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*, 2011, 12, s. 1004–1012.
- Pfizer Inc. Xalkori_o oral capsules (crizotinib): US prescribing information [online]. Dostupné z: <http://labeling.pfizer.com>, vyhledáno 27. 9. 2011.

Crizotinib – další reálná možnost personalizované léčby nemocných s NSCLC v České republice

prof. MUDr. Vítězslav Koleček, DrSc. Klinika plicních nemocí a TBC LF UP a FN Olomouc prof. MUDr. Miloš Pešek, CSc. Klinika plicních nemocí FN Plzeň prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC FN Brno MUDr. Ivona Grygárková Klinika plicních nemocí a TBC LF UP a FN Olomouc MUDr. Marcela Tomášková Klinika nemocí plicních a TBC FN Brno MUDr. Jaromír Roubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN Ostrava MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN Praha MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha MUDr. Helena Čoupková Klinika komplexní a onkologické péče MOÚ Brno

- Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- Debelenko, L. V. – Raimondi, S. C. – Daw, N., et al.: Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. *Modern Pathology*, 2011, 24, s. 430–442.
- Gainor, J. F. – Varghese, A. M. – Ou, S. H., et al.: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res*, 2013, 19, s. 4273–4281.
- Kwak, E. L. – Bang, Y.-J., Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- Rikova, K. – Guo, A. – Zeng, Q., et al.: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*, 2007, 131, s. 1190–1203.
- Heuckmann, J. M. – Hölzel, M. – Sos, M. L., et al.: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. *Clin Cancer Res*, 2011, 17, s. 7394–7401.
- Camidge, D. R. – Ou, I. S.-H. – Shapiro, G., et al.: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2014, 32, s. 355 (dopl.; abstrakt 8001).
- Minca, E. C. – Lanigan, C. P. – Reynolds, J. P., et al.: ALK status testing in non-small-cell lung carcinoma by FISH on thinprep slides with cytology material. *J Thorac Oncol*, 2014, 9, s. 464–468.
- www.pneumologie.cz, konsenzus laboratorní diagnostiky ALK translokace u nemocných s nemalobuněčným karcinomem plic.
- Camidge, R. – Bang, Y. J. – Kwak, E. L., et al.: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol*, 2012, 13, s. 1011–1019.
- Kim, D. W. – Ahn, M. J. – Shi, Y., et al.: Updated results of a global phase II study with crizotinib in advanced alk-positive non-small cell lung cancer (NSCLC). *ESMO*, 2012, kongres, abstrakt 1230PD.
- Shaw, A. T. – Kim, D. W. – Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*, 2013, 368, s. 2385–2394.
- Mok, T. – Kim, D. W. – Wu, Y.-L. – Solomon, B. J.: First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). *J Clin Oncol*, 2014, 32, 5s (dopl.), abstrakt 8002.
- Katayama, R. – Shaw, A. T. – Khan, T. N., et al.: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. *Sci Transl Med*, 2012, 4, 120ra, s. 17.
- Doebele, R. C. – Pilling, A. B. – Aisner, D. L., et al.: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res*, 2012, 18, s. 1472–1482.
- Ou, S. I. – Azada, M. – Hsiang, D. J., et al.: Next generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. *J Thorac Oncol*, 2014, 9, s. 549–553.
- Doebele, R. C. – Aisner, D. L. – Le, A. T., et al.: Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. 2012 ASCO Annual Meeting Abstracts. *J Clin Oncol*, 2012, 30, abstrakt 7504.
- Katayama, R. – Khan, T. M. – Benes, C., et al.: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci USA*, 2011, 108, s. 7535–7540.
- Camidge, D. – Bazhenova, L. – Salgia, R., et al.: Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. *J Thorac Oncol*, 2013, 8 (dopl. 2), s. S296–S297.
- Marsilje, T. H. – Pei, W. – Chen, B., et al.: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. *J Med Chem*, 2013, 56, s. 5675–5690.
- Shaw, A. T. – Mehra, R. – Kim, D., et al.: Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC, 2013 ASCO Annual Meeting Abstracts. *J Clin Oncol*, 2013, 31, abstrakt 8010.
- Gadgeel, S. – Ou, S. – Chiappori, A. A., et al.: A phase I dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028). *J Thorac Oncol*, 2013, 8 (dopl. 2), s. S199.

Gefitinib v první linii léčby nemalobuněčného karcinomu plic s prokázanou aktivační mutací genu EGFR u pacientů nad 80 let

MUDr. Markéta Černovská Pneumologická klinika 1. LF UK Praha/ Thomayerova nemocnice Praha

- 1 Peters, S., et al.: Metastatic Non-small-cell lung cancer. ESMO clinical Practise Quidelines, *Ann Oncol*, 2012, 23 (dopl. 7), s. vii56–vii64. 2 Skříčková, J. – Kolek, V.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2012. 3 Vašáková, M., et al.: *Moderní farmakoterapie v onkologii*, Maxdorf, Praha, 2013.

Ultibro® Breezhaler® – duální bronchodilatace fixní kombinací indakaterol/glykopyrronium v léčbě chronické obstrukční plicní nemoci

prof. MUDr. Vítězslav Kolek, DrSc. Klinika plicních nemocí a tuberkulózy, FN Olomouc

- 1 Gibson, G. J., et al.: The European lung white book. *ERS*, 2013, 42, s. 471. 2 Koblížek, V., et al.: *CHOPN. Doporučený postup ČPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci*. Maxdorf, 2013, s. 134. 3 Bateman, E. D., et al.: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. *Eur Respir J*, 2013, 42, s. 1484–1494. 4 Vogelmeier, C. F., et al.: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. *Lancet Respir Med*, 2013, 1, s. 51–60. 5 Wedzicha, J. A., et al.: Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med*, 2013, 1, s. 199–209. 6 Dahl, R., et al.: Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. *International Journal of COPD*, 2013, 8, s. 501–508. 7 Mahler, D. A., et al.: Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. *ERJ Express*, 2013, doi: 10.1183/09031936.00124013. 8 SPC Ultibro Breezhaler. 9 Rozhodnutí SUKL ze dne 18. 3. 2014, sp. zn. SUKL159524/2013.

Zánětlivé buňky u chronické obstrukční plicní nemoci

MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a TBC, FN a LF UP Olomouc

- 1 Rabe, K. F. – Hurd, S. – Anzueto, A.: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. *Am J Respir Crit Care Med*, 2007, 176, s. 532–555. 2 Barnes, P. J.: Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev*, 2004, 56, s. 515–548. 3 Kuna, P. – Jenkins, M. – O'Brien, C. D. – Fahy, W. A.: AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. *Respir Med*, 2012, 106, s. 531–539. 4 Churg, A., et al.: Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2012, 185, s. 34–43. 5 Zatloukal, J. – Navrátilová, Z. – Kolek, V. – Kriegová, E. – Petřek, M.: Vyšetření matrix-metaloproteináz a jejich inhibitorů v bronchoalveolární tekutině u pacientů s CHOPN a bronchiálním astmatem. *Stud Pneumol Phthiseol*, 2011, 4, s. 156–162. 6 Vlahos, R. – Wark, P. A. B. – Anderson, G. P. – Bozinovski, S.: Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. *PLoS One*, 2012, 7, e33277, doi: 10.1371/journal.pone.0033277. 7 Sapey, E., et al.: Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2011, 183, s. 1176–1186. 8 Schulz, C. – Wolf, K. – Harth, M. – Kratzel, K. – Kunz-Schughart, L. – Pfeifer, M.: Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers and never-smokers. *Respiration*, 2003, 70, s. 254–261. 9 Retamales, I. – Elliott, W. M. – Nesni, B. – Coxson, H. O. – Pare, P. D. – Sciruba, F. C. – Rogers, R. M. – Hayashi, S. – Hogg, J. C.: Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respir Crit Care Med*, 2001, 164, s. 469–473. 10 Traves, S. L. – Culpitt, S. V. – Russell, R. E. K. – Barnes, P. J. – Donnelly, L. E.: Elevated levels of the chemokines GRO- α and MCP-1 in sputum samples from COPD patients. *Toxax*, 2002, 57, s. 590–595. 11 Culpitt, S. V. – Rogers, D. F. – Shah, P. – de Matos, C. – Russell, R. E. – Donnelly, L. E. – Barnes, P. J.: Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2003, 167, s. 24–31. 12 Barczyk, A. – Pierzchala, W. – Kon, O. M. – Cosio, B. – Adcock, I. M. – Barnes, P. J.: Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. *J Allergy Clin Immunol*, 2006, 117, s. 1484–1492. 13 Boutten, A. – Bonay, M. – Laribe, S. – Lesech, G. – Castier, Y. – Lecon-Malas, V. – Fournier, M. – Furane, G. – Aubier, M. – Dehoux, M., et al.: Decreased expression of interleukin 13 in human lung emphysema. *Thorax*, 2004, 59, s. 850–854. 14 Schmidt-Weber, C. B. – Akdis, M. – Akdis, C. A.: TH17 cells in the big picture of immunology. *J Allergy Clin Immunol*, 2007, 120, s. 247–254. 15 Siva, R. – Green, R. H. – Brightling, C. E., et al.: Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. *Eur Respir J*, 2007, 29, s. 906–913. 16 Ye, L. – Wang, X. – Jin, M.: Role of Airway Epithelial Cells in Development of Chronic Obstructive Pulmonary Disease. *Journal of Epithelial Biology and Pharmacology*, 2009, 2, s. 44–50. 17 Koblížek, V. – Chlumský, J. – Zindr, V. – Neumannová, K. – Zatloukal, J. – Žák, J. – Sedláč, V. – Kociánová, J. – Zatloukal J. – Hejduk, K. – Prachařová, S.: Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. *Biomedical papers of the Medical Faculty of the University Palacky*, 2013, 157, s. 189–201.

Roflumilast ve světle nových doporučení pro léčbu chronické obstrukční plicní nemoci

MUDr. Michal Švarc Plicní klinika FN a LF UK, Hradec Králové

- 1 Barnes, P.: Immunology of asthma and chronic obstructive pulmonary disease. *Nature*, 2008, 8, s. 183–192. 2 Bourdin, A.: Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. *Eur Respir Rev*, 2009, 18, 114, s. 198–212. 3 Calverley, P., et al.: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*, 2009, 374, s. 685–694. 4 Grootendorst, D., et al.: Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. *Thorax*, 2007, 62, s. 1081–1087. 5 Hatzelmann, A., et al.: The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. *Pulmonary Pharmacology & Therapeutics*, 2010, 23, s. 235–256. 6 Hong, S. – Lee, S. H.: Role of Th17 cell and autoimmunity in chronic obstructive pulmonary disease. *Immune Network*, 2010, 10, 4, s. 109–114. 7 Koblížek, V., et al.: *Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN*, dostupné z: <http://www.pneumologie.cz/soubory/Standardverzekratka-korekce.2.6.2013.pdf>, vyhledáno 18. 5. 2014. 8 Milara, J., et al.: Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. *Allergy Clin Immunol*, 2014, online 17.03.2014

http://www.jacionline.org/article/S0091-6749(14)00183-3.

9 Papi, A., et al.: Pathophysiology of exacerbations of chronic obstructive pulmonary disease. *Proceedings of American Thoracic Society*, 2006, 3, s. 245–251.

10 Rabe, K.: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. *British Journal of Pharmacology*, 2011, 163, s. 53–67.

11 Vestbo, J.: COPD: Definition and phenotypes. *Clinics in Chest*

Medicine, 2014, 35, s. 1–6, dostupné z: <http://dx.doi.org/10.1016/j.ccm.2013.10.010>, vyhledáno 18. 5. 2014.

12 Wedzicha, J., et al.: Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. *CHEST*, 2013, 143, 5, s. 1302–1311.

13 White, W., et al.: Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. *CHEST*, dostupné z: <http://journal.publications.chestnet.org/>, vyhledáno 18. 5. 2014.

14 Wouters, E., et al.: Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naïve, newly diagnosed type 2 diabetes mellitus. *J Clin Endocrinol Metab*, 2012, doi: 10.1210/jc.2011–2886.

15 Wouters, E., et al.: Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Poster [C42] – prezentace 18. 5. 2010.

Současná bronchologie

MUDr. Jiří Votruba | MUDr. Hana Bartáková | MUDr. Juraj Šimovič 1. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha MUDr. Michal Šotola Centrum plicní endoskopie interního oddělení Nemocnice Na Homolce, Praha

1 <http://www.lifescienceintelligence.com/market-reports-page.php?id=hri-042>.

2 Jeremy, R. B.: Incidental findings on cardiac multidetector row computed tomography among healthy older adults. *Prevalence and Clinical Correlates Arch Intern Med*, 2008, 168, s. 756.

3 Momen, M. W.: Evidence for the treatment of patients with pulmonary nodules: When is it Lung Cancer ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). *CHEST*, 2007, 132, s. 945–1075.

4 Bronin, P.: Solitary pulmonary nodules: meta-analytic comparison of

cross-sectional imaging modalities for diagnosis of malignancy. *Radiology*, 2008, 246, s. 772.

5 Ost, D. – Fein, A. M. – Feinsilver, S. H.: Clinical practice: the solitary pulmonary nodule. *N Engl J Med*, 2003, 348, s. 2535–2542.

6 Niu, L. – Xu, K. – Mu, F.: Cryosurgery for Lung Cancer. *J Thorac Dis*, 2012, 4, s. 408–419.

7 Steinfurt, M., et al.: Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. *Eur Respir J*, 2011, 37, s. 902–910.

8 Lavore, I., et al.: 5-year safety of bronchial thermoplasty demonstrated in patients with severe refractory asthma: Research In Severe Asthma (RISA). *Trial Annals of Asthma, Allergy and Immunology*, 2013, In Press.

9 Wechsler, M., et al.: Benefits of bronchial thermoplasty persist out to 5 years in patients with severe asthma. *J Allergy Clin Immunol*, 2013 132 (6), s. 1295–1302, doi: 10.1016/j.jaci.2013.08.009, Epub 30. 8. 2013.

Asthma bronchiale: farmakoterapie u dospělých prizmatem doporučení GINA 2014

MUDr. Viktor Kašák LERYMED, s. r. o., Oddělení respiračních nemocí Praha

1 *Global strategy for asthma management and prevention*. Revidováno, 2014. GINA, 2014, dostupné z: www.ginasthma.org.

2 *Global strategy for asthma management and prevention*. Revidováno, 2014. Online doplněk, GINA, 2014, dostupné z: www.ginasthma.org.

3 *Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease*. GOLD Report. Revidováno, 2014, dostupné z: www.goldcopd.org.

4 Kolek, V., et al.: *Doporučené postupy v pneumologii*. Maxdorf, Jessenius, 2013, s. 460.

5 Koblížek, V. – Chlumský, J. – Zindr, V., et al.: *CHOPN. Doporučený postup CPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci*.

Maxdorf, Jessenius, 2013, s. 134.

6 Kolek, V. – Kašák, V. – Vašáková, M., et al.: *Pneumologie*, 2. vydání. Maxdorf, Jessenius, 2014, s. 607.

7 Kašák, V.: Asthma bronchiale. In: Kolek, V. – Kašák, V. – Vašáková, M., et al.: *Pneumologie*, 2. vydání. Maxdorf, Praha, 2014, s. 157–183.

8 Gonem, S. – Raj, V. – Wardlaw, A. T., et al.: Phenotyping airways Disease. An A to E approach. *Clin Exp Allergy*, 2012, 42, s. 1664–1683.

9 Louie, S. – Zeki, A. A. – Schivo, M., et al.: The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. *Expert Rev Clin Pharmacol*, 2013, 6, s. 197–219.

10 Miravittles, M. – Soriano, J. B. – Ancochea J., et al.: Characterisation

of the overlap COPD-asthma phenotype. Focus on physical activity and health status. *Respir Med*, 2013, 107, s. 1053–1060.

11 Pauk, N.: Fenotyp překryvu CHOPN s astmatem (ACOS). *Farmakoterapie*, 2014, 10, s. 54–58.

12 Magnussen, H. – Bugnas, B. – van Noord, J., et al.: Improvements with tiotropium in COPD patients with concomitant asthma. *Respir Med*, 2008, 102, s. 50–56.

13 Kerstjens, H. A. M. – Engel, M. – Dahl, R., et al.: Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med*, 2012, 367, s. 1198–1207.

Problematické těžké asthma bronchiale

MUDr. Vratislav Sedlák, Ph.D. | MUDr. Ondřej Kudela | MUDr. Vladimír Koblížek, Ph.D.
Plicní klinika LF a FN Hradec Králové, UK v Praze

1 Bateman, E.: *GINA – Global Initiative for Asthma Document*. 2011.

2 Teřil, M. – Pohunek, P.: *Strategie diagnostiky, prevence a léčby astmatu. Uvedení globální strategie do praxe v ČR*. 2012, Praha. Česká iniciativa pro astma, o. p. s.

3 Haldar, P. – Pavord, I. D. – Shaw, D.: Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med*, 2008, 178, s. 218–224.

4 Bateman, E. D. – Clark, T. J. – Frith, L. – Bousquet, J., et al.: Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the GOAL study. *J Asthma*, 2007, 44, s. 667–673.

5 Bel, E. H. – Sousa, A. – Flemming, L., et al.: On behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement form the Innovative Medicine Initiative (IMI). *Thorax*, 2011, 66, s. 910–917.

6 Chung, K. F. – Godard, P. – Adelroth, E., et al.: Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma.

European Respiratory Society. *Eur Respir J*, 1999, 13, s. 478–483.

7 Hastie, A. T. – Moore, W. C. – Meyers, D. A., et al.: National Heart, Lung, and Blood Institute Severe Asthma Research Program Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. *J Allergy Clin Immunol*, 2010, 125, s. 1028–1036.

8 Sedlák, V. – Chlumský, J. – Teřil, M. – Novotná, B., et al.: Doporučený postup pro diagnostiku a léčbu obtížně léčitelného astmatu v České republice. *Studia pneumologica et phthiseologica*, 2011, 71, s. 65–75.

9 Leung, D. M. Y. – Hamid, Q. – Vottero, A. – Szefer, S. – Surs, W., et al.: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β . *J Exp Medicine*, 1997, 186, s. 1567–1574.

10 Barnes, P. J.: Severe asthma: Advances in current management and future therapy. *J Allergy Clin Immunol*, 2012, 129, s. 48–59.

11 Chung, K. F. – Gibeon, D. – Durham, A. – Marwick, J., et al.: Corticosteroids: use and insensitivity in severe asthma. *Eur Respir Mon*, 2011, 51, s. 236–252.

12 Boulet, L. P. B.: Irreversible airway obstruction in asthma. *Curr Allergy Asthma Reports*, 2009, 9, s. 168–173.

13 Bel, E. H. – ten Brinke, A. – Sorkness, R. L.: Fixed airway obstruction

in severe asthma. *Eur Respir Mon*, 2011, 51, s. 147–159.

14 Wenzel, S.: Asthma: defining of the persistent adult phenotypes. *Lancet*, 2006, 368, s. 804–813.

15 Moore, W. C. – Bleeker, E. R. – Curran-Everett, D., et al.: Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institutes Severe Asthma Research Program. *J Allergy Clin Immunol*, 2007, 119, s. 405–413.

16 Bousquet, J. – Mantzouranis, E. – Cruz, A. A., et al.: Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol*, 2010, 126, s. 926–938.

17 Ting, A. – Murray, C. S.: Treatment-resistant asthma: options and decision making. *Pediatric Health*, 2010, 4, s. 433–446.

18 Bachert, C. – Zhang, N.: The upper airways in severe asthma. *Eur Respir Mon*, 2011, 51, s. 189–190.

19 Parsons, J. P. – Mastrorade, J. G.: Gastroesophageal reflux disease and asthma. *Curr Opin Pulm Med*, 2010, 16, s. 60–63.

20 Mastrorade, J. G. – Anthonisen, N. R. – Castro, M., et al.: Efficacy of esomeprazole for treatment of poorly controlled asthma. *N Engl J Med*, 2009, 360, s. 1487–1499.

- 21 **Foster, J. M.** – Lavoie, K. L. – Boulet, L. P.: Treatment adherence and psychosocial factors in severe asthma. *Eur Respir Mon*, 2011, 51, s. 28–49.
- 22 **Chanez, P.** – Wenzel, S. E. – Anderson, G. P.: Severe asthma in adults: what are the important questions. *J Allergy Clin Immunol*, 2007, 119, s. 973–984.
- 23 **Low, K.** – Lau, K. K. – Holmes, P. – Crossett, M., et al.: Abnormal vocal cord function in difficult-to-treat asthma. *Am J Respir Crit Care Med*, 2010, 184, s. 50–56.
- 24 **Sideleva, O.** – Suratt, B. T. – Black, S. E. – Dixon, A. E.: Obesity and asthma. An inflammatory disease of adipose tissue not the airway. *Am J Respir Crit Care Med*, 2012, 186, s. 598–605.
- 25 **Menzies-Gow, A.** – Gibeon, D. – Hui, C. – Zhang, Q., et al.: Management of difficult-to-treat severe asthma. *Eur Respir Mon*, 2011, 51, s. 282–296.
- 26 **Sedlák, V.** – Koblížek, V.: Budoucí léčba astma bronchiale. *Klinická farmakologie a farmacie*, 2010, 24, s. 71–74.
- 27 **Simpson, J. L.** – Powell, H. – Boyle, M. J. – Scott, R. J. – Gibson, P. G.: Clarithromycin targets neutrophilic inflammation in refractory asthma. *Am J Respir Crit Care Med*, 2008, 2008, s. 148–155.
- 28 **Brussele, G. B.** – Vander Stichele, Ch. – Jordens, P., et al.: Azithromycin for prevention of exacerbations in severe asthma (AZISAST) a multicentre randomised double-blind placebo-controlled trial. *Thorax*, 2013, 68, s. 322–329.
- 29 **Szczeklik, A.** – Picado, C.: Aspirin-induced asthma. *Eur Respir Mon*, 2003, 23, s. 239–248.
- 30 **Humbert, M.** – Beasley, R. – Ayres, J., et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy*, 2005, 60, s. 309–316.
- 31 **Haldar, P.** – Brightling, C. E. – Hardagon, B. – Pavord, D. I., et al.: Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med*, 2009, 360, s. 973–984.
- 32 **Sedlák, V.** – Král, B. – Salajka, F.: Alternativní léčba obtížně léčitelného astmatu. *Farmakoterapie*, 2006, 1, s. 61–67.
- 33 **Castro, M.** – Rubin, A. S. – Laviolette, M., et al.: Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *Am J Respir Crit Care Med*, 2010, 181, s. 116–124.

Cystická fibróza dospělých

MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN Motol

- 1 **Aris, R. M.** – Merkel, P. A. – Bachrach, L. K., et al.: Guide to bone health and disease in cystic fibrosis. *J Clin Endocrinol Metab*, 2005, 90, s. 1888–1896.
- 2 **Bhatt, J. M.**: Treatment of pulmonary exacerbations in cystic fibrosis. *Eur Respir Rev*, 2013, 22, s. 205–216.
- 3 **Boucher, R. C.**: New concepts of the pathogenesis of cystic fibrosis lung disease. *Eur Respir J*, 2004, 23, s. 146–158.
- 4 **Colombo, C.** – Ellemunter, H. – Houwen, R., et al.: ECFs. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. *J Cyst Fibros*, 2011, 10, s. S24–S28.
- 5 **Debray, D.** – Kelly, D. – Houwen, R., et al.: Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. *J Cyst Fibros*, 2011, 10, s. S29–S36.
- 6 **Edenborough, F. P.** – Borgo, G. – Knoop, C., et al.: European Cystic Fibrosis Society. Guidelines for the management of pregnancy in women with cystic fibrosis. *J Cyst Fibros*, 2008, 7, s. S2–S32.
- 7 **Fila, L.**: Farmakoterapie cystické fibrózy. *Remedia*, 2010, 20, s. 374–378.
- 8 **Fila, L.**: Cystická fibróza. In: Kolek, V., et al.: *Pneumologie*. Maxdorf, Praha, 2011, s. 386–390.
- 9 **Griffith, D. E.** – Aksamit, T. – Brown-Elliott, B. A., et al.: ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*, 2007, 175, s. 367–416.
- 10 **Kelly, A.** – Moran, A.: Update on cystic fibrosis-related diabetes. *J Cyst Fibros*, 2013, 12, s. 318–331.
- 11 **Mogayzel, P. J. Jr.** – Naureckas, E. T. – Robinson, K. A., et al.: Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. *Am J Respir Crit Care Med*, 2013, 187, s. 680–689.
- 12 **Mousa, H. M.** – Woodley, F. W.: Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. *Curr Gastroenterol Rep*, 2012, 14, s. 226–235.
- 13 **Olivier, K. N.** – Weber, D. J. – Lee, J. H., et al.: Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. *Am J Respir Crit Care Med*, 2003, 167, s. 835–840.
- 14 **Ramsey, B. W.** – Davies, J. – McElvaney, N. G., et al.: VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med*, 2011, 365, s. 1663–1672.
- 15 **Saiman, L.** – Siegel, J.: Infection control in cystic fibrosis. *Clin Microbiol Rev*, 2004, 17, s. 57–71.
- 16 **Rowe, S. M.** – Miller, S. – Sorscher, E. J.: Cystic fibrosis. *N Engl J Med*, 2005, 352, s. 1992–2001.
- 17 **Sinaasappel, M.** – Stern, M. – Littlewood, J., et al.: Nutrition in patients with cystic fibrosis: a European Consensus. *J Cyst Fibros*, 2002, 1, s. 51–75.
- 18 **Stevens, D. A.** – Moss, R. B. – Kurup, V. P., et al.: Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. *Clin Infect Dis*, 2003, 37, s. S225–S264.
- 19 **Walkowiak, J.** – Lisowska, A. – Blaszczczyński, M.: The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype. *Eur J Gastroenterol Hepatol*, 2008, 20, s. 157–160.
- 20 **Wong, P. Y.**: CFTR gene and male fertility. *Mol Hum Reprod*, 1998, 4, s. 107–110.
- 21 **Yankaskas, J. R.** – Marshall, B. C. – Sufian, B., et al.: Cystic fibrosis adult care: consensus conference report. *Chest*, 2004, 125, s. 15–39S.

Léčba akutního srdečního selhání

MUDr. Tomáš Janota, CSc. 3. interní klinika VFN a 1. LF UK, Praha

- 1 McMurray, J. J. V., on behalf of the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *European Heart Journal*, 2012, 33, s. 1787–1847, doi: 10.1093/eurheartj/ehs104.

Léčba průjmových onemocnění

MUDr. Helena Ambrožová, Ph.D. I. infekční klinika 2. LF UK a Nemocnice Na Bulovce

- 1 www.EPIDAT.cz.
2 Guarino, A. – Albano, F. – Ashkenazi, S., et al.: European Society for Paediatric Gastroenterology, Hepatology and Nutrition/European Society for Paediatric Infectious Diseases Evidence-based Guidelines for the Management of Acute Gastroenteritis in Children in Europe. *J Pediatr Gastroenterol Nutr*, 2008, 46, s. 581–5122.
3 Churgay, C. A. – Aftab, Z.: Gastroenteritis in children. Part II. Prevention and management. *Am Fam Physician*, 2012, 85, s. 1066–1070.
4 Guarino, A. – Dupont, C. – Gorelov, A. V., et al.: The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. *Expert Opin Pharmacother*, 2012, 13, s. 17–26.
5 Nevoral, J.: Prebiotika a probiotika v pediatrii. *Praktické lékárenství: časopis postgraduálního vzdělávání pro farmaceuty*, 2012, 8, s. 217–224.
6 Dupont, Ch. – Kok Foo, J. L. – Garnier, P., et al.: Oral diosmectite reduces stool output and diarrhea duration in children with acute watery diarrhea. *Clin Gastroenterol Hepatol*, 2009, 17, s. 456–462.
7 Salari, P. – Nikfar, J. – Abdollahi, M., et al.: A meta-analysis and systematic review of the effect of probiotics in acute diarrhea. *Inflamm Allergy Drug Targets*, 2012, 11, s. 3–14.
8 Nyč, O. – Matějková, J. – Obuch-Woszczatynski, P., et al.: Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. *Lancet*, 2011, 37, s. 1407.
9 Gough, E. – Shaikh, H. – Manges, A. R.: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. *Clin Inf Dis*, 2011, 53, s. 994–1002.
10 Van Nood, E. – Vrieze, A. – Nieuwdorp, M., et al.: Duodenal infusion of donor feces for recurrent clostridium difficile. *New Engl J Med*, 2013, 368, s. 407–414.
11 Senior, K.: Faecal transplantation for recurrent C difficile diarrhoea. *Lancet Inf Dis*, 2013, 13, s. 200–201.

Narušení cirkadiánních rytmů a civilizační choroby

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Lu, W. – Meng, Q.-J. – Tyller, N. J. C. – Stokkan, K.-A. – Loudon, A. S. I.: A circadian clock is not required in an arctic mammals. *Current Biology*, 2010, 20, s. 533–537.
2 Zantke, J. – Ishikawa-Fujiwara, T. – Arboleda, E. – Lohs, C. – Schipany, K. – Halley, N. – Straw, A. D. – Todo, T. – Tessmar-Raible, K.: Circadian and circalunar clock interactions in a marine annelid. *Cell Reports*, 2013, 5, s. 99–113.
3 Bøggild, H. – Knutsson, A.: Shift work, risk factors and cardiovascular disease. *Scandinavian Journal of Work and Environmental Health*, 1999, 25, s. 85–99.
4 Garaulet, M. – Gómez-Abellán, P. – Albuquerque-Béjar, J. J. – Lee, Y.-C. – Ordovás, J. M. – Scheer, F. A. J. L.: Timing of food intake predicts weight loss effectiveness. *International Journal of Obesity*, 2013, 37, s. 604–611.
5 Arble, D. M. – Bass, J. – Laposky, A. D. – Vitaterna, M. H. – Turek, F. W.: Circadian timing of food intake contributes to weight gain. *Obesity*, 2009, 17, s. 2100–2102.
6 Vollmers, C. – Gill, S. – DiTacchio, L. – Pulivarthy, S. R. – Le, H. D. – Panda, S.: Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. *Proceedings of the National Academy of Science*, 2009, 106, s. 21453–21458.
7 Hoogerwerf, W. A. – Hellmich, H. L. – Cornélissen, G. – Halberg, F. – Shahinian, V. B. – Bostwick, J. – Savidge, T. C. – Cassone, V. M.: Clock gene expression in the murine gastrointestinal tract: Endogenous rhythmicity and effects of a feeding regimen. *Gastroenterology*, 2007, 133, s. 1250–1260.
8 Hatori, M. – Vollmers, C. – Zarrinpar, A. – DiTacchio, L. – Bushong, E. – Gill, S. – Leblanc, M. – Chaix, A. – Joens, M. – Fitzpatrick, J. A. J. – Ellisman, M. H. – Panda, S.: Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. *Cell Metabolism*, 2012, 15, s. 848–860.
9 Paschos, G. K. – Ibrahim, S. – Song, W.-L. – Kunieda, T. – Grant, G. – Reyes, T. M. – Bradfield, C. A. – Cheryl, H. – Vaughan, C. H. – Eiden, M. – Masoodi, M. – Griffin, J. L. – Wang, F. – Lawson, J. A. – Fitzgerald, G. A.: Obesity in mice with adipocyte-specific deletion of clock component Arntl. *Nature Medicine*, 2012, 18, s. 1768–1777.
10 Marcheva, B. – Ramsey, K. M. – Buhr, E. D. – Kobayashi, Y. – Su, H. – Ko, C. H. – Ivanova, G. – Omura, C. – Mo, S. – Vitaterna, M. H. – Lopez, J. P. – Philipson, L. H. – Bradfield, C. A. – Crosby, S. D. – JeBailey, L. – Wang, X. – Takahashi, J. S. – Bass, J.: Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature*, 2010, 466, s. 627–631.
11 Feng, D. – Liu, T. – Sun, Z. – Bugre, A. – Mullican, S. E. – Alenghat, T. – Liu, X. S. – Lazar, M. A.: A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. *Science*, 2011, 331, s. 1315–1319.
12 Ramsey, K. M. – Tshibobo, J. – Brace, C. S. – Abrassart, D. – Kobayashi, Y. – Marcheva, B. – Hong, H.-K. – Chiny, J. L. – Buhr, E. D. – Lee, C. – Takahashi, J. S. – Imai, S.-I. – Bass, J.: Circadian clock feedback cycle through NAMPT-mediated NAD⁺ biosynthesis. *Science*, 2009, 324, s. 651–654.